Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) Question and Answer Webinar Special Notice

SOL #: ARPA-H-SN-26-148Special Notice

Overview

Buyer

Health And Human Services
National Institutes Of Health
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Washington, DC, 20005, United States

Place of Performance

Washington, DC

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

Health R&D Services; Health Care Services; Experimental Development (AN13)

Set Aside

No set aside specified

Timeline

1
Posted
Feb 6, 2026
2
Action Date
Feb 10, 2026, 10:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Advanced Research Projects Agency for Health (ARPA-H) has issued a Special Notice announcing a Question and Answer (Q&A) Webinar for the Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program. This webinar aims to clarify the ADVOCATE Innovation Solutions Opening (ISO), ARPA-H-SOL-26-142, and address questions from the Proposers' Day held on January 23, 2026. Webinar registration closes on February 10, 2026, at 5:00 PM EST.

Purpose

This Special Notice serves to alert the scientific community to the ARPA-H ADVOCATE program and invite potential proposers to a non-mandatory Q&A Webinar. The session, sponsored by the Scalable Solutions Office (SSO), will provide additional clarification on the ADVOCATE ISO, which focuses on enabling the utilization of safe and effective agentic Artificial Intelligence (AI) technology by healthcare organizations to provide 24/7 specialty care to patients with chronic Cardiovascular Disease (CVD).

Program Details

The ADVOCATE program is structured as a two-phase, 39-month initiative, including a 12-month Base Period and two Option Periods (12 and 15 months). It involves three main technical areas:

  • TA1 (CVD Agent): For patient care management.
  • TA2 (Supervisory Agent): For continuous monitoring and control of deployed agents.
  • TA3: Focuses on scalable implementation by healthcare organizations.

Webinar Logistics

  • Date & Time: February 12, 2026, from 12:30 PM to 2:00 PM ET.
  • Format: Virtual Q&A session.
  • Registration: Opens February 6, 2026, at 8:00 AM EST and closes February 10, 2026, at 5:00 PM EST.
  • Capacity: Capped at 500 attendees on a first-come, first-serve basis.
  • Recording: The webinar will be recorded and made available on the ADVOCATE webpage.

Important Notes

Attendance at this Q&A Webinar is voluntary and not a prerequisite for submitting a solution summary or proposal in response to the ADVOCATE ISO. This notice is for informational purposes only and does not constitute a formal solicitation. ARPA-H is not obligated to respond to or provide feedback on information submitted in response to this Special Notice. The ADVOCATE ISO (ARPA-H-SOL-26-142) is available on SAM.gov.

People

Points of Contact

SEE DESCRIPTION SECTIONPRIMARY

Files

Files

Download

Versions

Version 1Viewing
Special Notice
Posted: Feb 6, 2026
Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) Question and Answer Webinar Special Notice | GovScope